129799-08-2

Basic information

• Product Name: METHYL 4-BOC-PIPERAZINE-2-CARBOXYLATE
• Synonyms: 4-N-BOC-PIPERAZINE-2-CRBOXYLIC ACID METHYL ESTER-HCl;N-4-BOC-piperazine-2-carboxylic acid Methyl ester-HCl;1-Boc-piperazine-3-carboxylic acid Methyl ester;1,3-Piperazinedicarboxylicacid, 1-(1,1-diMethylethyl) 3-Methyl ester;1-O-tert-butyl 3-O-methyl piperazine-1,3-dicarboxylate;METHYL 4-BOC-PIPERAZINE-2-CARBOXYLATE;METHYL 4N-BOC-PIPERAZINE-2-CARBOXYLATE;1-TERT-BUTYL-3-METHYL-PIPERAZINE-1,3-DICARBOXYLATE
• CAS NO: 129799-08-2
• Molecular Formula: C₁₁H₂₀N₂O₄
• Molecular Weight: 244.29
• Product Categories: pharmacetical;Piperaizine
• Mol File: 129799-08-2.mol

Chemical Properties

• Boiling Point: 321.3 °C at 760 mmHg
• Flash Point: 148.1 °C
• Appearance: /
• Density: 1.118 g/cm³
• Vapor Pressure: 0.000301mmHg at 25°C
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• Solubility: Soluble in dimethyl sulfoxide.
• PKA: 6.45±0.40(Predicted)
• CAS DataBase Reference: METHYL 4-BOC-PIPERAZINE-2-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 4-BOC-PIPERAZINE-2-CARBOXYLATE(129799-08-2)
• EPA Substance Registry System: METHYL 4-BOC-PIPERAZINE-2-CARBOXYLATE(129799-08-2)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 129799-08-2(Hazardous Substances Data)

Usage

Uses

It is used as pharmaceutical intermediate.

InChI:InChI=1/C11H20N2O4/c1-11(2,3)17-10(15)13-6-5-12-8(7-13)9(14)16-4/h8,12H,5-7H2,1-4H3/p+1/t8-/m1/s1

Upstream product

• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 2758-98-7 2-methoxycarbonyltetrahydropyrazine 
• 128019-59-0 piperazine-1,3-dicarboxylic acid 1-tert-butyl ester 
• 74-88-4 methyl iodide 
• 126937-42-6 piperazine-1,2,4-tricarboxylic acid 1-benzyl ester 4-tert-butyl ester 2-methyl ester 
• 2762-32-5 piperazine-2-carboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 126937-41-5 1-(benzyloxycarbonyl)-4-(tert-butoxycarbonyl)-2-piperazinecarboxylic acid 
• 98-97-5 2-pyrazylcarboxylic acid 
• 122323-88-0 piperazine-2-carboxylic acid methyl ester dihydrochloride 
• 129799-15-1 piperazine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester 
• 67-56-1 methanol 
• 181955-79-3 N,N'-di-tert-butyloxycarbonylpiperazine-2-carboxylic acid 

Downstream Products

• 871338-85-1 1-(1,1-dimethylethyl) 3-methyl 4-(3-chlorophenyl)piperazine-1,3-dicarboxylate 
• 863329-79-7 1-[(3-methoxy-4-tert-butylphenyl)carbonyl]-piperazine-2,4-dicarboxylic acid 2-methyl ester 4-tert-butyl ester 
• 1350459-99-2 1-tert-butyl 3-methyl 4-(2-cyano-4-nitrophenyl)piperazine-1,3-dicarboxylate 
• 1350456-86-8 3-benzyl-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine 
• 1350456-87-9 3-benzyl-6-(4-bromobenzyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine 
• 1350456-93-7 3,6-dibenzyl-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine 
• 1350457-03-2 (3-benzyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepin-6(7H)-yl)(morpholin-4-yl)methanone 
• 1350457-35-0 3-(4-fluorobenzyl)-2,3,4,4a,6,7-hexahydropyrazino[1,2-a][1,4]benzodiazepin-5(1H)-one 
• 1350457-38-3 3-(4-fluorobenzyl)-1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine 

Relevant articles and documents

Method for synthesizing monoamine-protected piperazine-(R/S)2-formate

The invention discloses a method for synthesizing monoamine-protected piperazine-(R/S)2-formate, wherein the method comprises the steps: by using 2-piperazinecarboxylate as a raw material, protecting1,4-site amines by using different protective groups, and salifying by using different chiral amines, resolving to obtain a single chiral compound; and finally, using pyridine or DMAP and other pyridine analogues as an alkali, reacting oxalyl chloride, triphosgene, phosgene, thionyl chloride and other similar acyl chlorides in anhydrous tetrahydrofuran, 2-methyl tetrahydrofuran or toluene and other solvents, and finally adding methanol, ethanol, isopropanol, benzyl alcohol and other alcohol reagents to generate the target product capable of removing carboxylic acid ortho-amino protecting groups in a positioned manner and esterifying carboxylic acid. Amino groups on piperazine are separately protected through simple three-step reaction, chiral resolution is performed by utilizing the characteristics of acid, finally, protonated intermediates are formed through organic alkali and carboxylic acid, anhydride is formed by the protonated intermediates and ortho-amino groups, formic acid esterification is performed by utilizing alcohol to replace ring opening, and a final product is obtained.

KRAS G12C INHIBITORS

The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

KRAS G12C INHIBITORS

The present invention relates to compounds that, inhibit KRas G12C, In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

KRAS G12C INHIBITORS

The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

KRAS G12C INHIBITORS

The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

(PIPERIDIN-3-YL)(NAPHTHALEN-2-YL)METHANONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HISTONE DEMETHYLASE KDM2B FOR THE TREATMENT OF CANCER

The present invention relates to (piperidin-3-yl)(naphthalen-2-yl) methanone derivatives and related compounds as inhibitors of one or more histone demethylses, such as KDM2b. The invention also provides pharmaceutically acceptable compositions comprising

SATURATED BICYCLIC HETEROCYCLIC DERIVATIVES AS SMO ANTAGONISTS

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of the Sonic Hedgehog pathway, in particular Smoantagonists. Thus the compounds of this invention are useful for the treatment of diseases associated with abnormal hedgehog pathway activation, including cancer, for example basal cell carcinoma, medulloblastoma, prostate, pancreatic, breast, colon, bone and small cell lung cancers, and cancers of the upper GI tract.

4-ACYL-PIPERAZINES AS ANTI-VIRAL AGENTS

Anti-viral agents of Formula (I) wherein: A represents hydroxy or -NH2; D represents aryl or heteroaryl; E represents hydrogen, straight or branched chain C1-6alkyl, -CO2R1, -C(O)R1a, -C(O)NR2/s

The relationship between physicochemical properties, in vitro activity and pharmacokinetic profiles of analogues of diamine-containing efflux pump inhibitors

Following the optimization of diamine-containing efflux pump inhibitors with respect to in vitro potentiation activity, in vivo stability and acute toxicity, we addressed the question of how to control the pharmacokinetic properties of the series. Upon in

Heterocyclic substituted aniline calcium channel blockers

The present invention provides compounds that block calcium channels having the Formula I shown below. STR1The present invention also provides methods of using the compounds of Formula I to treat stroke, cerebral ischemia, head trauma, epilepsy, asthma, amyotrophic lateral sclerosis, or pain and to pharmaceutical compositions that contain the compounds of Formula I.